An air deodorant for intensive care unit and its preparation method

Abstract

The present invention discloses an air deodorant for intensive care units and a preparation method thereof, belonging to the field of deodorants. The air deodorant includes component A and component B; component A is a solid adsorption carrier, and component B is a capsule treatment agent, and component B is evenly distributed on component A; component A includes the following components in parts by weight: 100 parts of graphene-modified activated carbon, 50 parts of molecular sieve, 5-6 parts of silane coupling agent; the outer shell of the capsule in component B includes the following components in parts by weight: 50-52 parts of beeswax, 30 parts of glycerol monostearate, 10 parts of polarity-modified polyethylene, 3-4 parts of nano-metal oxide; the inner core of the capsule includes the following components in parts by weight: 60-70 parts of yucca extract esterified and modified by short-chain compounds, 80 parts of volatile solvent, 10 parts of propylene glycol, 5 parts of essence, 15 parts of xanthan gum. The deodorant component mainly composed of yucca extract in this application can partially volatilize into the air and react with substances such as ammonia and hydrogen sulfide in the air, playing a role in deodorization.

Description

Technical Field

[0001] The present invention belongs to the field of deodorants, and relates to an air deodorant for intensive care units and a preparation method thereof. Background Art

[0002] Most of the patients in the intensive care unit are critically ill or severely ill and cannot control their own excretion; therefore, the air in the intensive care unit not only has the smell of disinfectant and blood, but also is mixed with the obvious smell of excrement; in order to ensure that the air in the intensive care unit is clean, deodorants are often used to remove the smell in the intensive care unit; the commonly used deodorant at present is activated carbon, which is a solid deodorant and will not adhere to equipment or patients in large quantities, and is safer to use compared with spray deodorants; however, the deodorization efficiency of the activated carbon deodorant is low and it will quickly reach adsorption saturation. Summary of the Invention

[0003] The purpose of the present invention is to provide an air deodorant for intensive care units and a preparation method thereof, which solves the problems of low deodorization efficiency and short service life of the activated carbon deodorant in the existing intensive care unit.

[0004] The technical solution adopted by the present invention is as follows:

[0005] An air deodorant for intensive care units, comprising component A and component B, and the mass ratio of component A to component B is 1:1.7 - 2; the component A is a solid adsorption carrier, and the component B is a capsule treatment agent, and the component B is evenly distributed on the component A;

[0006] The component A comprises the following components in parts by weight: 100 parts of graphene-modified activated carbon, 50 parts of molecular sieve, 5 - 6 parts of silane coupling agent;

[0007] The outer shell of the capsule in the component B comprises the following components in parts by weight: 50 - 52 parts of beeswax, 30 parts of glycerol monostearate, 10 parts of polar-modified polyethylene, 3 - 4 parts of nano metal oxide; the inner core of the capsule comprises the following components in parts by weight: 60 - 70 parts of yucca extract esterified and modified with short-chain compounds, 80 parts of volatile solvent, 10 parts of propylene glycol, 5 parts of essence, 15 parts of xanthan gum.

[0008] The present application provides an air deodorant used in a heating environment at 50°C. In a heating environment at about 50°C, the deodorizing component mainly composed of yucca extract can partially volatilize into the air, react with substances such as ammonia and hydrogen sulfide in the air, reduce the concentration of odor substances such as ammonia and hydrogen sulfide in the air, and thus play a role in volatilizing and deodorizing.

[0009] Yucca extract itself is a substance that is not easily volatile. In order to improve the volatility of yucca extract, the present invention esterifies and modifies yucca extract with short-chain compounds and mixes the modified yucca extract with a volatile solvent. On the one hand, through the esterification reaction, the macromolecular compounds in yucca extract are converted into small-molecule esters. These small-molecule esters have lower boiling points and are more likely to evaporate, thus improving the overall volatility. On the other hand, the rapid evaporation of the volatile solvent can carry the yucca extract to evaporate quickly, further increasing the evaporation rate of yucca extract;

[0010] After the volatility of yucca extract is improved, its stability becomes poor and it is not easy to store. Therefore, in this application, a treatment agent mainly composed of yucca extract esterified and modified with short-chain compounds and a volatile solvent is used as the core substance, and a capsule structure is prepared in cooperation with the shell substance. The capsule shell blocks the contact between the core substance and the outside world, and can effectively prevent the evaporation of yucca extract esterified and modified with short-chain compounds, volatile solvents, etc. during storage, improving the storage stability of the treatment agent;

[0011] The outer shell of the treatment agent capsule in the present invention mainly consists of beeswax. Beeswax will quickly melt under heating conditions, releasing the inner core substance inside, and will not significantly reduce the deodorization efficiency of the inner core substance. However, after beeswax solidifies, its surface is smooth and has a low polarity, making it difficult to firmly adhere to the carrier. Moreover, its mechanical strength is low and its heat conduction effect is poor, affecting the thermal response and use stability of the capsule outer shell. Therefore, based on beeswax, the present invention adds glycerol monostearate, polar-modified polyethylene, and nano-metal oxide. On the one hand, glycerol monostearate can jointly regulate the melting point of the capsule outer shell with beeswax, enabling the capsule outer shell to quickly melt at a temperature of about 50°C. On the other hand, glycerol monostearate can also strengthen the adhesion between the capsule outer shell and the carrier. Glycerol monostearate is a non-ionic surfactant, and its molecule contains polar groups and non-polar groups. The polar groups can form hydrogen bonds with the surface of the carrier, thereby improving the adhesion of the capsule outer shell to the carrier. The non-polar groups are compatible with beeswax, improving the surface wettability of beeswax and making it easier to adhere to the surface of the carrier. Polar-modified polyethylene is mainly used to improve the mechanical strength of the capsule outer shell. Nano-metal oxide is used to enhance the thermal conductivity and mechanical strength of the capsule outer shell. Beeswax has poor compatibility with polar-modified polyethylene and nano-metal oxide. Glycerol monostearate can reduce the interfacial tension between beeswax and other components, promoting uniform mixing. The melting point of polyethylene is relatively high, and through polar modification, its melting point can be reduced so that it does not affect the melting point of the capsule outer shell. If the melting point of the capsule outer shell is too high, a higher temperature is required to melt it. However, high temperature will not only cause the inner core substance to volatilize rapidly in a short time, increasing the usage amount of the inner core substance and shortening the duration of continuous deodorization, but also significantly increase the temperature inside the intensive care unit. The temperature inside the intensive care unit cannot be too high, and too high a temperature will affect the patient's condition. The present invention combines the overall deodorization efficiency of the deodorant, the duration of continuous deodorization, and the impact on the temperature inside the intensive care unit, and limits the use temperature of the deodorant in this application to about 50°C.

[0012] The present invention modifies activated carbon to make it have good heat conduction effect, and synergistically acts with the capsule wall with heat conduction function to strengthen the thermal response of the capsule wall.

[0013] After the capsule wall melts, the inner core substance is released. On the one hand, it volatilizes to deodorize; on the other hand, the liquid substance is adsorbed on the solid carrier. The solid carrier realizes the adsorption of odor substances, and the liquid substance realizes the decomposition of odor substances, which can improve the deodorization effect, and also improve the adsorption saturation of activated carbon and extend the service life of activated carbon. The combination of volatilization deodorization and adsorption deodorization has high deodorization efficiency and good effect.

[0014] Furthermore, the short-chain compound esterified modified yucca extract is prepared by the following method:

[0015] A1. Protecting the active hydroxyl group: Dissolve the yucca extract in anhydrous pyridine, add tert-butyldimethylchlorosilane and 4-dimethylaminopyridine, stir and react at room temperature for 12 hours. After the reaction, purify by column chromatography, elute with an eluent, collect the fraction containing the protected yucca extract, and concentrate to obtain the protected yucca extract; wherein, the ratio of the yucca extract to anhydrous pyridine is 1:10 g / ml, the mass ratio of tert-butyldimethylchlorosilane to the yucca extract is 1.5:1, and the addition amount of 4-dimethylaminopyridine is 5% of the mass of the yucca extract.

[0016] B1. Esterification reaction: Mix the protected yucca extract with glacial acetic acid and a small amount of concentrated sulfuric acid, heat and stir in an oil bath at 50 °C for 6 hours and then cool. After cooling, add saturated sodium carbonate solution to neutralize the excessive acid until the solution is neutral; then extract with ethyl acetate, separate the organic phase and the aqueous phase, collect the organic phase, dry with anhydrous sodium sulfate, filter and concentrate to obtain the crude product; wherein the ratio of the yucca extract to glacial acetic acid is 1:5 g / ml, and the ratio of the yucca extract to concentrated sulfuric acid is 1:0.25 g / ml.

[0017] C1. Deprotection: Dissolve the crude product in dichloromethane, add tetrabutylammonium fluoride, stir at room temperature for 4 - 6 hours. After the reaction, purify by column chromatography, elute with an eluent, collect the fraction containing the esterification-modified yucca extract, and concentrate to obtain the yucca extract modified by short-chain compounds through esterification; wherein, the mass ratio of tetrabutylammonium fluoride to the crude product is 1.5:1.

[0018] In the esterification process of the present invention, by protecting the activity, the volatility of the yucca extract is improved without affecting its activity.

[0019] Further, the graphene-modified activated carbon is prepared by the following method:

[0020] A2. Add graphene oxide powder to deionized water to prepare a dispersion of 1 - 5 mg / mL, and then use ultrasonic treatment for 60 minutes to obtain a graphene oxide dispersion.

[0021] B2. Alternately wash the activated carbon with deionized water and ethanol, and then dry it at 60 - 80 °C for standby.

[0022] C2. Add the dried activated carbon to the graphene oxide dispersion, stir and mix, use ultrasonic treatment for 30 minutes, then let it stand for 12 hours, and then filter, wash and dry to obtain graphene oxide-coated activated carbon.

[0023] D2. Put the graphene oxide-coated activated carbon into a tube furnace, and introduce an inert gas. The inert gas is N 2Or Ar, exclude air, maintain an inert atmosphere, heat to 900 °C at a heating rate of 5 - 10 °C / min, hold at 900 °C for 1 hour, and naturally cool to room temperature to obtain graphene-modified activated carbon;

[0024] Among them, in step C2, the mass ratio of graphene oxide to activated carbon is 1:10.

[0025] Furthermore, the volatile solvent includes ethyl acetate and ethanol, and the mass ratio of ethyl acetate to ethanol is 1:2.

[0026] Furthermore, in the outer shell of the capsule in component B, there are also 20 - 22 parts of acrylic acid-modified poly(N-isopropylacrylamide), and the preparation method of the acrylic acid-modified poly(N-isopropylacrylamide) is as follows:

[0027] A3. Mix N-isopropylacrylamide and acrylic acid in a mass ratio of 9:1 and dissolve them in deionized water to prepare a monomer solution;

[0028] B3. Under stirring and heating, add ammonium persulfate accounting for 1% of the total mass of the monomers to the monomer solution, raise the temperature to 50 °C and react for 1 hour, then add N,N'-methylenebisacrylamide accounting for 0.5% of the total mass of the monomers, under nitrogen protection, raise the temperature to 60 °C, and react for 6 hours. After the reaction, purify and dry to obtain acrylic acid-modified poly(N-isopropylacrylamide).

[0029] The acrylic acid-modified poly(N-isopropylacrylamide) is in a gel state within 50 °C. After cross-linking with other components of the capsule shell, the prepared capsule shell has good flexibility, which is beneficial to improving the flexibility of the capsule, reducing the brittleness of the capsule, and ensuring stable use; in addition, the acrylic acid-modified poly(N-isopropylacrylamide) has thermosensitivity. When the capsule shell melts, the acrylic acid-modified poly(N-isopropylacrylamide) is released to form a gel-like substance, and the gel-like substance will enhance the adhesion of the core substance on the solid carrier, enabling the core substance to be heated evenly; when the temperature is higher than 50 °C, the molecular chains of the acrylic acid-modified poly(N-isopropylacrylamide) dehydrate and contract to form a hydrophobic aggregated state, and the structure hardens, which will lock part of the core substance on the solid carrier. Compared with the component without adding acrylic acid-modified poly(N-isopropylacrylamide), the volatilization rate of the core substance at the current temperature is reduced, avoiding all the core substance from volatilizing in a short time. At this time, the solid carrier can mainly adsorb the odor substance in the solid carrier, and then decompose the odor substance through the core substance on the solid carrier for deodorization treatment.

[0030] Furthermore, the nano metal oxides in component B include nano zinc oxide and nano alumina, and the mass ratio of nano zinc oxide to nano alumina is 1:3.

[0031] Further, the molecular sieve in Component A includes MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve, and Beta zeolite, and the mass ratio of MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve, and Beta zeolite is 1:2:1.

[0032] Further, the polar-modified polyethylene is low-density linear polyethylene grafted with maleic anhydride.

[0033] Further, Component B is prepared by the following method:

[0034] A4. Add beeswax, glycerol monostearate, and polar-modified polyethylene into a reaction kettle, heat to 70 - 80 °C, and stir until completely melted to obtain a first intermediate;

[0035] B4. Add nano metal oxide into the first intermediate and stir evenly to obtain a second intermediate;

[0036] C4. Dissolve poly(N-isopropylacrylamide) modified with acrylic acid in an appropriate amount of deionized water, then add N,N'-methylenebisacrylamide and ammonium persulfate, stir evenly, add the second intermediate, stir evenly, heat to 70 °C, react for 2 hours, cool to 40 °C after the reaction, and keep it in a liquid state to obtain the capsule shell material for standby; wherein, the addition amount of N,N'-methylenebisacrylamide is 0.5% of the mass of poly(N-isopropylacrylamide) modified with acrylic acid, and the addition amount of ammonium persulfate is 0.5% of the mass of poly(N-isopropylacrylamide) modified with acrylic acid;

[0037] D4. Dissolve the short-chain compound esterified and modified yucca extract in a volatile solvent, add propylene glycol, essence, and xanthan gum, and stir evenly to form a uniform core solution;

[0038] E4. Slowly add the core solution into the liquid capsule shell material, add an emulsifier, and emulsify with a high-speed shear emulsifier. Keep the temperature at 50 °C during the emulsification process, and cool at room temperature after the emulsification to obtain Component B.

[0039] The preparation method of an air deodorant for an intensive care unit includes the following steps:

[0040] S1. Prepare Component A: Activate the molecular sieve at 200 - 300 °C for 2 - 3 hours to remove moisture and impurities; dissolve the silane coupling agent in ethanol, stir evenly to obtain a silane coupling agent solution; prepare graphene-modified activated carbon, then mix the graphene-modified activated carbon, the activated molecular sieve, and the silane coupling agent solution, stir evenly, and dry at 60 - 80 °C to obtain Component A;

[0041] S2. Prepare Component B using capsule preparation technology;

[0042] S3. Uniformly spray the prepared component B on component A, stir and mix evenly, and then air-dry at room temperature for 2 - 3 hours to obtain the final air deodorant.

[0043] In summary, due to the adoption of the above technical solutions, the beneficial effects of the present invention are as follows:

[0044] 1. An air deodorant for an intensive care unit of the present invention uses a modified yucca extract as a treatment agent, significantly improving the volatility of the yucca extract. Under heating conditions, it can not only deodorize by relying on the polarity of the volatile treatment agent, but also deodorize through the synergistic effect of activated carbon, molecular sieve, and yucca extract, with dual deodorization and high efficiency.

[0045] 2. During the esterification modification of the yucca extract of the present invention, by protecting the activity, the volatility is improved without affecting the activity of the yucca extract.

[0046] 3. The present invention prepares the treatment agent into a capsule structure, which is beneficial for storing volatile internal substances.

[0047] 4. The present invention adds poly(N-isopropylacrylamide) modified with acrylic acid to the capsule shell. When the temperature of the deodorant is higher than the applicable temperature, poly(N-isopropylacrylamide) modified with acrylic acid will lock up some core substances, reducing the volatilization rate of the core substances at the current temperature and avoiding a large amount of volatilization of the core substances in a short time, having the performance of preventing high-temperature loss. Specific Embodiments

[0048] In order to make the objectives, technical solutions, and advantages of the present invention clearer, the following further elaborates on the present invention in combination with embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention, that is, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Usually, the components of the embodiments of the present invention described and illustrated herein can be arranged and designed in various different configurations.

[0049] Therefore, the detailed description of the embodiments of the present invention provided below is not intended to limit the scope of the claimed present invention, but only represents the selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative efforts fall within the scope of protection of the present invention.

[0050] It should be noted that relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual relationship or order between these entities or operations. Moreover, the terms "comprising", "including" or any other variant thereof are intended to cover non-exclusive inclusion, such that a process, method, article or device comprising a series of elements not only includes those elements, but also includes other elements not expressly listed, or also includes elements inherent to such process, method, article or device. Without further limitation, an element defined by the statement "comprising an..." does not exclude the presence of additional identical elements in the process, method, article or device comprising the element.

[0051] The features and performance of the present invention will be further described in detail below in conjunction with embodiments.

[0052] Embodiment 1

[0053] An air deodorant for an intensive care unit provided by a preferred embodiment of the present invention includes component A and component B, and the mass ratio of component A to component B is 1:1.7; component A is a solid adsorption carrier, and component B is a capsule treatment agent, and component B is uniformly distributed on component A;

[0054] Component A includes the following components in parts by weight: 100 parts of graphene-modified activated carbon, 50 parts of molecular sieve, 5-6 parts of silane coupling agent;

[0055] The outer shell of the capsule in component B includes the following components in parts by weight: 50-52 parts of beeswax, 30 parts of glycerol monostearate, 10 parts of polar-modified polyethylene, 3-4 parts of nano metal oxide; the inner core of the capsule includes the following components in parts by weight: 60-70 parts of short-chain compound esterified modified yucca extract, 80 parts of volatile solvent, 10 parts of propylene glycol, 5 parts of essence, 15 parts of xanthan gum.

[0056] The short-chain compound esterified modified yucca extract is prepared by the following method:

[0057] A1. Protect the active hydroxyl group: Dissolve the yucca extract in anhydrous pyridine, add tert-butyldimethylchlorosilane and 4-dimethylaminopyridine, stir and react at room temperature for 12 hours. After the reaction is completed, purify by column chromatography, elute with an eluent, collect the fraction containing the protected yucca extract, and concentrate to obtain the protected yucca extract; wherein, the ratio of the yucca extract to anhydrous pyridine is 1:10 g / ml, the mass ratio of tert-butyldimethylchlorosilane to the yucca extract is 1.5:1, and the addition amount of 4-dimethylaminopyridine is 5% of the mass of the yucca extract;

[0058] B1. Esterification reaction: The protected yucca extract is mixed with glacial acetic acid and a small amount of concentrated sulfuric acid, heated and stirred in an oil bath at 50 °C for 6 hours, and then cooled. After cooling, saturated sodium carbonate solution is added to neutralize the excess acid until the solution is neutral. Then, extraction is carried out with ethyl acetate to separate the organic phase and the aqueous phase. The organic phase is collected, dried with anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The ratio of yucca extract to glacial acetic acid is 1:5 g / ml, and the ratio of yucca extract to concentrated sulfuric acid is 1:0.25 g / ml.

[0059] C1. Deprotection: The crude product is dissolved in dichloromethane, tetrabutylammonium fluoride is added, and the mixture is stirred at room temperature for 4 - 6 hours. After the reaction is completed, it is purified by column chromatography, eluted with an eluent, and the fraction containing the esterified modified yucca extract is collected and concentrated to obtain the esterified modified yucca extract of the short-chain compound. Among them, the mass ratio of tetrabutylammonium fluoride to the crude product is 1.5:1.

[0060] The graphene-modified activated carbon is prepared by the following method:

[0061] A2. Add graphene oxide powder to deionized water to prepare a dispersion with a concentration of 5 mg / mL, and then use ultrasonic treatment for 60 minutes to obtain a graphene oxide dispersion.

[0062] B2. The activated carbon is alternately washed with deionized water and ethanol and then dried at 60 - 80 °C for standby.

[0063] C2. Add the dried activated carbon to the graphene oxide dispersion, stir and mix, use ultrasonic treatment for 30 minutes, then let it stand for 12 hours, and then filter, wash, and dry to obtain graphene oxide-coated activated carbon.

[0064] D2. Put the graphene oxide-coated activated carbon into a tubular furnace, introduce an inert gas, the inert gas is N 2 or Ar, exclude air, maintain an inert atmosphere, heat it to 900 °C at a heating rate of 5 - 10 °C / min, keep it at 900 °C for 1 hour, and naturally cool to room temperature to obtain graphene-modified activated carbon.

[0065] Among them, in step C2, the mass ratio of graphene oxide to activated carbon is 1:10.

[0066] The volatile solvent includes ethyl acetate and ethanol, and the mass ratio of ethyl acetate to ethanol is 1:2.

[0067] The molecular sieve in component A includes MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve, and Beta zeolite, and the mass ratio of MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve, and Beta zeolite is 1:2:1.

[0068] The polar-modified polyethylene is a maleic anhydride-grafted low-density linear polyethylene.

[0069] The component B is prepared by the following method:

[0070] A4. Add beeswax, glycerol monostearate and polar-modified polyethylene into a reaction kettle, heat to 70 - 80 °C, and stir until completely melted to obtain a first intermediate;

[0071] B4. Add nano metal oxide into the first intermediate and stir evenly to obtain a liquid capsule shell material;

[0072] C4. Dissolve the short-chain compound-esterified yucca extract in a volatile solvent, add propylene glycol, essence and xanthan gum, and stir evenly to form a uniform core solution;

[0073] D4. Slowly add the core solution into the liquid capsule shell material, add an emulsifier, and emulsify with a high-speed shear emulsifier. Keep the temperature at 50 °C during the emulsification process, and cool at room temperature after the emulsification ends to obtain component B.

[0074] The preparation method of an air deodorant for an intensive care unit includes the following steps:

[0075] S1. Prepare component A: Activate the molecular sieve at 200 - 300 °C for 2 - 3 hours to remove moisture and impurities; dissolve the silane coupling agent in ethanol and stir evenly to obtain a silane coupling agent solution; prepare graphene-modified activated carbon, and then mix the graphene-modified activated carbon, the activated molecular sieve and the silane coupling agent solution, stir evenly, and dry at 60 - 80 °C to obtain component A;

[0076] S2. Prepare component B using capsule preparation technology;

[0077] S3. Evenly spray the prepared component B on component A, stir and mix evenly, and air-dry at room temperature for 2 - 3 hours to obtain the final air deodorant.

[0078] Example 2

[0079] Based on Example 1, in this example, the shell of the capsule in component B further includes 20 - 22 parts of acrylic acid-modified poly(N-isopropylacrylamide), and the preparation method of the acrylic acid-modified poly(N-isopropylacrylamide) is as follows:

[0080] A3. Mix N-isopropylacrylamide and acrylic acid in a mass ratio of 9:1 and dissolve them in deionized water to prepare a monomer solution;

[0081] B3. Under stirring and heating conditions, add ammonium persulfate accounting for 1% of the total mass of the monomers to the monomer solution, heat up to 50 °C and react for 1 hour, then add N,N'-methylenebisacrylamide accounting for 0.5% of the total mass of the monomers. Under nitrogen protection, heat up to 60 °C and react for 6 hours. After the reaction is completed, purify and dry to obtain acrylic acid-modified poly(N-isopropylacrylamide).

[0082] The nano metal oxides in the component B include nano zinc oxide and nano alumina, and the mass ratio of nano zinc oxide to nano alumina is 1:3.

[0083] The component B is prepared by the following method:

[0084] A4. Add beeswax, glycerol monostearate and polar-modified polyethylene to the reaction kettle, heat to 70 - 80 °C, and stir until completely melted to obtain the first intermediate.

[0085] B4. Add nano metal oxides to the first intermediate and stir evenly to obtain the second intermediate.

[0086] C4. Dissolve acrylic acid-modified poly(N-isopropylacrylamide) in an appropriate amount of deionized water, then add N,N'-methylenebisacrylamide and ammonium persulfate, stir evenly, add the second intermediate, stir evenly, heat up to 70 °C, react for 2 hours, and after the reaction is completed, cool to 40 °C and keep it in a liquid state to obtain the capsule shell material for standby; among them, the addition amount of N,N'-methylenebisacrylamide is 0.5% of the mass of acrylic acid-modified poly(N-isopropylacrylamide), and the addition amount of ammonium persulfate is 0.5% of the mass of acrylic acid-modified poly(N-isopropylacrylamide).

[0087] D4. Dissolve the short-chain compound-esterified yucca extract in a volatile solvent, add propylene glycol, essence and xanthan gum, and stir evenly to form a uniform core solution.

[0088] E4. Slowly add the core solution to the liquid capsule shell material, add an emulsifier, and emulsify with a high-speed shear emulsifier. Keep the temperature at 50 °C during the emulsification process, and cool at room temperature after the emulsification is completed to obtain the component B.

[0089] Example 3

[0090] This example is based on Example 2. The difference from Example 2 is that the mass ratio of component A to component B is 1:1.8.

[0091] Example 4

[0092] This example is based on Example 2. The difference from Example 2 is that the mass ratio of component A to component B is 1:2.

[0093] Comparative Example 1

[0094] Based on Example 2, what is different in this example is that the mass ratio of Component A to Component B is 1:1.6.

[0095] Comparative Example 2

[0096] Based on Example 2, what is different in this example is that the mass ratio of Component A to Component B is 1:2.1.

[0097] Comparative Example 3

[0098] Based on Example 2, what is different in this example is that the capsule shell of Component B includes 20 - 22 parts of poly(N-isopropylacrylamide) and does not include acrylic acid-modified poly(N-isopropylacrylamide).

[0099] Comparative Example 4

[0100] Based on Example 2, what is different in this example is that Component A does not include graphene-modified activated carbon.

[0101] Comparative Example 5

[0102] Based on Example 2, what is different in this example is that Component A does not include molecular sieves.

[0103] Comparative Example 6

[0104] Based on Example 2, what is different in this example is that the activated carbon in Component A has not been modified with graphene.

[0105] Comparative Example 7

[0106] Based on Example 1, what is different in this example is that Component B is only composed of the core material, including 60 - 70 parts of short-chain compound-esterified yucca extract, 80 parts of volatile solvent, 10 parts of propylene glycol, 5 parts of essence, and 15 parts of xanthan gum. The core material is directly sprayed on Component A to form a deodorant, and Component B is not in a capsule structure.

[0107] Comparative Example 8

[0108] Based on Example 2, what is different in this example is that the yucca extract in Component B has not been modified and is a conventional yucca extract.

[0109] Comparative Example 9

[0110] Based on Example 2, what is different in this example is that Component B does not add glycerol monostearate to its shell.

[0111] Comparative Example 10

[0112] Based on Example 2, the difference in this example is that no polar-modified polyethylene is added to the outer shell of Component B.

[0113] Comparative Example 11

[0114] Based on Example 2, the difference in this example is that no nano metal oxide is added to the outer shell of Component B.

[0115] Comparative Example 12

[0116] Based on Example 2, the difference in this example is that unmodified polyethylene is used to replace polar-modified polyethylene in the outer shell of Component B.

[0117] Comparative Example 13

[0118] Based on Example 2, the difference in this example is that xanthan gum is not added to the inner core of Component B.

[0119] Comparative Example 14

[0120] Based on Example 2, the difference in this example is that propylene glycol is not added to the inner core of Component B.

[0121] Comparative Example 15

[0122] Based on Example 2, the difference in this comparative example is that the deodorant only includes Component A and does not include Component B.

[0123] Comparative Example 16

[0124] Based on Example 2, the difference in this comparative example is that the deodorant only includes Component B and does not include Component A.

[0125] Test Example 1

[0126] Detect the deodorization efficiency of Examples 1 - 4 and Comparative Examples 1 - 16;

[0127] The detection method of deodorization efficiency is as follows: Using ammonia and hydrogen sulfide gas as reference substances, detect the concentration of ammonia and hydrogen sulfide gas before and after treatment. Deodorization efficiency = (concentration before treatment - concentration after treatment) / concentration before treatment × 100%; Detection conditions: 100 g of Component A, detection space of 10 m³, initial space temperature of 24 °C, placed in a heating tank at 50 °C, target odor substances: hydrogen sulfide (H 2 S) and ammonia (NH 3), The detection time is 30 minutes, and the initial concentrations of hydrogen sulfide and ammonia are 10 ppm and 20 ppm respectively. Multiple gas sampling points are set in the space to collect gas samples before and after treatment; multiple temperature detection points are set in the space to detect the initial temperature (24 °C) before deodorization treatment and the final temperature after 30 minutes of deodorization, and the temperature change rate is detected. The values of multiple detection points are calculated separately and then averaged. Temperature change rate = (final temperature - initial temperature) / initial temperature × 100%; The results are shown in Table 1.

[0128] Table 1 Detection results of deodorization efficiency and temperature change

[0129] Hydrogen sulfide deodorization efficiency Ammonia deodorization efficiency Temperature change rate Example 1 ＞98% ＞95% ＜4% Example 2 ＞98% ＞95% ＜4% Example 3 ＞98% ＞95% ＜4% Example 4 ＞98% ＞95% ＜4% Comparative Example 1 96.8-97.1% 92.5-93% ＜4% Comparative Example 2 98.3-98.5% 95.3-95.9% ＜4% Comparative Example 3 96.7-97% 91-92.2% ＜4% Comparative Example 4 ＜70% ＜80% ＜4% Comparative Example 5 80-81% 84.5-85.1% ＜4% Comparative Example 6 79.6-81% 85.7-86.2% ＜4% Comparative Example 7 96.1-96.2% 90-91% ＜4% Comparative Example 8 ＜70% ＜70% ＜4% Comparative Example 9 96.8-97% 91-92% ＜4% Comparative Example 10 ＞98% ＞95% ＜4% Comparative Example 11 95.8-96.2% 91.1-92% ＜4% Comparative Example 12 ＜60% ＜70% ＜4% Comparative Example 13 96.8-97% 92.5-93% ＜4% Comparative Example 14 96.7-96.8% 93.1-93.5% ＜4% Comparative Example 15 58.5-58.6% 60.1-61.3% ＜4% Comparative Example 16 61.8-62.1% 64.2-64.5% ＜4%

[0130] In the present invention, the deodorant is used under the heating condition of 50 °C. This use condition has little impact on the ambient temperature, can cause the ambient temperature to rise, but the rising degree is within 1 °C and will not cause too much impact in the intensive care unit; the ammonia removal rate of the present invention under the above conditions reaches more than 95%, and the hydrogen sulfide removal rate reaches more than 98%, showing obvious deodorization effect. In the present invention, reducing the dosage of component B will affect the deodorization efficiency; however, too much dosage of component B will block component A, affect the adsorption of component A, and also affect the deodorization efficiency. In the present invention, if the deodorant volatilizes into the air in a large amount in a short time, it will cause too high a local concentration, which not only wastes the deodorant, but also causes competition between deodorant molecules due to the too high concentration, reducing the effective collision probability with odor molecules, thus affecting the deodorization efficiency. Moreover, when a large amount of deodorant volatilizes in the air, the smell of the deodorant in the air will be too strong, which instead affects the freshness of the indoor air, and the too strong smell is likely to cause discomfort to the indoor personnel.

[0131] Test Example 2

[0132] In a dry environment, the moisture absorption and volatilization effects of component A are not obvious. Therefore, the weight change of component A within 30 minutes in a dry environment is very small and can be basically ignored; the volatilization of component B in the deodorants of Test Examples 1-4 and Comparative Examples 1-14 was detected at different temperatures, and the detection temperatures were 25 °C, 40 °C, 50 °C, and 60 °C;

[0133] The detection method is as follows: Place the deodorant sample in a constant-temperature drying environment, and detect the weight loss rate of the sample placed at 25 °C, 40 °C, 50 °C, and 60 °C for 30 minutes respectively. The higher the weight loss rate, the faster the volatilization speed. Measure the initial weight W0 of the capsule sample using a precision balance. After 30 minutes of the experiment, end the measurement and record the final weight W30. Weight loss rate = (W0 - W30) / W0 × 100%. The detection results are shown in Table 2.

[0134] Table 2 Detection results of the volatilization speed of component B

[0135] 25℃ 40℃ 50℃ 60℃ Example 1 ＜0.1% ＜0.1% 1-2% ＞4% Example 2 ＜0.1% ＜0.1% 1-2% 2-2.2% Example 3 ＜0.1% ＜0.1% 1-2% 2-2.2% Example 4 ＜0.1% ＜0.1% 1-2% 2-2.2% Comparative Example 1 ＜0.1% ＜0.1% 1-2% 2-2.2% Comparative Example 2 ＜0.1% ＜0.1% 2.2-2.5% 3-3.1% Comparative Example 3 ＜0.1% ＜0.1% ＜1% 1-2% Comparative Example 4 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 5 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 6 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 7 1-2% 10-15% ＞20% ＞20% Comparative Example 8 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 9 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 10 ＜0.1% ＜0.1% 1-2% 2-2.2% Comparative Example 11 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 12 ＜0.1% ＜0.1% ＜1% ＜1% Comparative Example 13 ＜0.1% ＜0.1% 1-2% 2-2.2% Comparative Example 14 ＜0.1% ＜0.1% 1-2% 2-2.2%

[0136] In the present invention, component B is substantially non-volatile at 25°C, and the capsule structure has a good protective effect on component B; after the temperature in the present invention exceeds 50°C, component B added with poly(N-isopropylacrylamide) modified with acrylic acid has a slower volatilization rate than component B without poly(N-isopropylacrylamide) modified with acrylic acid, which can effectively avoid the excessive volatilization situation caused by too high temperature.

[0137] Test Example 3

[0138] Detect the compressive strength of the capsule shell of component B in Test Examples 1 and 2, and Comparative Examples 3, 9, 10, 11, and 12. The detection method is the prior art, and the detection results are shown in Table 3 for reference.

[0139] Table 3 Compressive Strength of the Capsule Outer Wall

[0140]

[0141] The capsule of component B in the present invention has good compressive strength, which meets the normal use and storage of the capsule-type deodorant.

[0142] The above are only the preferred embodiments of the present invention, and are not intended to limit the protection scope of the present invention. Any modifications, equivalent substitutions, and improvements made by those skilled in the art within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. An air deodorizer for an intensive care room, characterized in that: It comprises component A and component B, wherein the mass ratio of component A to component B is 1:1.7-2; the component A is a solid adsorption carrier, the component B is a capsule treatment agent, and the component B is evenly distributed on the component A; The component A comprises the following components in parts by weight: 100 parts of graphene-modified activated carbon, 50 parts of molecular sieve, and 5-6 parts of silane coupling agent; The shell of the capsule in component B comprises the following components in parts by weight: 50-52 parts of beeswax, 30 parts of glyceryl monostearate, 10 parts of polar modified polyethylene, and 3-4 parts of nano metal oxides; the inner core of the capsule comprises the following components in parts by weight: 60-70 parts of yucca extract modified by esterification of short-chain compounds, 80 parts of volatile solvents, 10 parts of propylene glycol, 5 parts of flavors, and 15 parts of xanthan gum; The short-chain compound esterified modified yucca extract is prepared by the following method: A1. Protecting active hydroxyl groups: dissolving the yucca extract in anhydrous pyridine, adding tert-butyldimethylsilyl chloride and 4-dimethylaminopyridine, stirring and reacting at room temperature for 12 hours, and after the reaction, purifying by column chromatography, eluting with an eluent, collecting fractions containing the protected yucca extract, and concentrating to obtain the protected yucca extract; wherein the ratio of the yucca extract to anhydrous pyridine is 1:10 g / ml, the mass ratio of tert-butyldimethylsilyl chloride to the yucca extract is 1.5:1, and the amount of 4-dimethylaminopyridine added is 5% of the mass of the yucca extract; B1. Esterification reaction: the protected yucca extract is mixed with glacial acetic acid and a small amount of concentrated sulfuric acid, heated and stirred in a 50°C oil bath for 6 hours and then cooled. After cooling, a saturated sodium carbonate solution is added to neutralize the excess acid until the solution is neutral; then extracted with ethyl acetate, the organic phase and the aqueous phase are separated, the organic phase is collected, dried with anhydrous sodium sulfate, filtered and concentrated to obtain a crude product; wherein the ratio of yucca extract to glacial acetic acid is 1:5 g / ml, and the ratio of yucca extract to concentrated sulfuric acid is 1:0.25 g / ml; C1. Deprotection: dissolving the crude product in dichloromethane, adding tetrabutylammonium fluoride, stirring at room temperature for 4-6 hours, and after the reaction is completed, purifying by column chromatography, eluting with an eluent, collecting the fraction containing the esterified modified yucca extract, and concentrating to obtain the short-chain compound esterified modified yucca extract; wherein the mass ratio of tetrabutylammonium fluoride to the crude product is 1.5:1; The graphene-modified activated carbon is prepared by the following method: A2, adding graphene oxide powder to deionized water to prepare a dispersion of 5 mg / mL, and then subjecting the mixture to ultrasonic treatment for 60 minutes to obtain a graphene oxide dispersion; B2. Wash the activated carbon with deionized water and ethanol alternately and dry it at 60-80°C for later use; C2, adding the dried activated carbon to the graphene oxide dispersion, stirring and mixing, using ultrasonic treatment for 30 minutes and then standing for 12 hours, then filtering, washing and drying to obtain graphene oxide-coated activated carbon; D2, placing the activated carbon coated with graphene oxide in a tube furnace, introducing an inert gas, wherein the inert gas is Ar, excluding air, maintaining an inert atmosphere, heating to 900°C at a heating rate of 5-10°C / min, maintaining at 900°C for 1 hour, and naturally cooling to room temperature to obtain graphene-modified activated carbon; Wherein, in step C2, the mass ratio of graphene oxide to activated carbon is 1:10; The polar modified polyethylene is a low-density linear polyethylene grafted with maleic anhydride.

2. The air deodorizer for an intensive care room according to claim 1, characterized in that: The volatile solvent includes ethyl acetate and ethanol, and the mass ratio of ethyl acetate to ethanol is 1:

2.

3. The air deodorizer for an intensive care room according to claim 1, characterized in that: The capsule shell in the component B also includes 20-22 parts of acrylic acid-modified poly-N-isopropylacrylamide, and the preparation method of the acrylic acid-modified poly-N-isopropylacrylamide is as follows: A3, dissolving N-isopropylacrylamide and acrylic acid in deionized water at a mass ratio of 9:1 to prepare a monomer solution; B3. Under stirring and heating, add 1% of ammonium persulfate by weight of the total monomer to the monomer solution, heat to 50°C and react for 1 hour, then add 0.5% of N,N'-methylenebisacrylamide by weight of the total monomer, heat to 60°C under nitrogen protection and react for 6 hours. After the reaction, purify and dry to obtain acrylic acid-modified poly (N-isopropylacrylamide).

4. The air deodorizer for an intensive care room according to claim 1, characterized in that: The nano metal oxide in the component B includes nano zinc oxide and nano aluminum oxide, and the mass ratio of nano zinc oxide to nano aluminum oxide is 1:

3.

5. The air deodorizer for an intensive care room according to claim 1, characterized in that: The molecular sieves in the component A include MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve and Beta zeolite, and the mass ratio of MCM-41 mesoporous molecular sieve, 13X zeolite molecular sieve and Beta zeolite is 1:2:

1.

6. The air deodorizer for an intensive care room according to claim 3, characterized in that: The component B is prepared by the following method: A4, adding beeswax, glyceryl monostearate and polar modified polyethylene into a reaction kettle, heating to 70-80° C., and stirring until completely melted to obtain a first intermediate; B4, adding nano metal oxide to the first intermediate, stirring evenly, to obtain a second intermediate; C4, dissolving acrylic acid-modified poly-N-isopropylacrylamide in an appropriate amount of deionized water, then adding N,N'-methylenebisacrylamide and ammonium persulfate, stirring evenly, adding the second intermediate, stirring evenly, heating to 70°C, reacting for 2 hours, cooling to 40°C after the reaction, keeping the liquid state, and obtaining a capsule shell material for standby use; wherein, the amount of N,N'-methylenebisacrylamide added is 0.5% of the mass of acrylic acid-modified poly-N-isopropylacrylamide, and the amount of ammonium persulfate added is 0.5% of the mass of acrylic acid-modified poly-N-isopropylacrylamide; D4, dissolving the yucca extract modified by esterification of short-chain compounds in a volatile solvent, adding propylene glycol, flavor and xanthan gum, and stirring evenly to form a uniform core solution; E4. Slowly add the inner core solution into the liquid capsule shell material, add an emulsifier, and emulsify using a high-speed shear emulsifier. During the emulsification process, the temperature is maintained at 50° C. After the emulsification is completed, cool at room temperature to obtain component B.

7. A method for preparing an air deodorant for an intensive care room according to any one of claims 1 to 6, characterized in that: The following steps are involved: S1. Preparation of component A: activating the molecular sieve at 200-300° C. for 2-3 hours to remove moisture and impurities; Dissolving a silane coupling agent in ethanol and stirring evenly to obtain a silane coupling agent solution; preparing graphene-modified activated carbon, and then mixing the graphene-modified activated carbon, the activated molecular sieve and the silane coupling agent solution, stirring evenly, and drying at 60-80° C. to obtain component A; S2. preparing component B using capsule preparation technology; S3. Spray the prepared component B evenly on the component A, stir and mix evenly, and then air-dry at room temperature for 2-3 hours to obtain the final air deodorant.

Images